DKN-01 Plus Bevacizumab/Chemotherapy Advances to Part B in DeFianCe Trial in Advanced CRC
Leap Therapeutics has launched the randomized, controlled part B of the phase 2 DeFianCe trial, which will evaluate DKN-01 in combination with bevacizumab and chemotherapy as second-line therapy in patients with advanced colorectal cancer.
Zeva Wainberg Cynthia Sirard Ucla Gi Oncology Program Leap Therapeutics Inc Leap Therapeutics Defiance Trial
Source: onclive.com